Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Saad

Showing results (11-20 of 161) with videos related to

Pageof 17
Sort By:
Current Opinion in Oncology|June 17, 2020
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpointsEverardo D Saad, Marc Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsE D Saad, M Buyse
Neural Computation|September 1, 1995
Learning and generalization in radial basis function networksJ A Freeman, D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
CALGB 9633: an underpowered trial with a methodologically questionable conclusionArtur Katz, Everardo D Saad
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|July 20, 2001
Noise, regularizers, and unrealizable scenarios in online learning from restricted training setsY S Xiong, D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?Everardo D Saad, Marc Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2016
Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'E D Saad, M Buyse
European Heart Journal. Acute Cardiovascular Care|February 8, 2024
Rethinking survival analysis: advancing beyond the hazard ratio?Johan Verbeeck, Everardo D Saad
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|January 7, 2003
Random graph coloring: statistical physics approachJ van Mourik, D Saad
Revista Do Hospital Das Clinicas|January 1, 1996
[Evidence-based medicine]E D Saad, H Grunspun
Pageof 17

Showing results (11-20 of 161) with videos related to

Sort By:
Pageof 17
Current Opinion in Oncology|June 17, 2020
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpointsEverardo D Saad, Marc Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsE D Saad, M Buyse
Neural Computation|September 1, 1995
Learning and generalization in radial basis function networksJ A Freeman, D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
CALGB 9633: an underpowered trial with a methodologically questionable conclusionArtur Katz, Everardo D Saad
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|July 20, 2001
Noise, regularizers, and unrealizable scenarios in online learning from restricted training setsY S Xiong, D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?Everardo D Saad, Marc Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2016
Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'E D Saad, M Buyse
European Heart Journal. Acute Cardiovascular Care|February 8, 2024
Rethinking survival analysis: advancing beyond the hazard ratio?Johan Verbeeck, Everardo D Saad
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|January 7, 2003
Random graph coloring: statistical physics approachJ van Mourik, D Saad
Revista Do Hospital Das Clinicas|January 1, 1996
[Evidence-based medicine]E D Saad, H Grunspun
Pageof 17